🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Glofitamab plus chemotherapy with GemOx enhanced PFS and OS outcomes vs rituximab plus GemOx in relapsed/refractory diffuse large B-cell lymphoma. #lymsm #ASCO25 hubs.li/Q03qyBvt0

Neoadjuvant sacituzumab govitecan with pembrolizumab demonstrated pathologic complete responses in patients with early-stage triple-negative breast cancer, according to findings from arm A2 of the phase 2 NeoSTAR study. #bcsm #ASCO25 hubs.li/Q03qyH8J0

Results from HERTHENA-Lung02 did not show improved OS with patritumab deruxtecan in patients with EGFR-mutated NSCLC. #lcsm #NSCLC #ASCO25 hubs.li/Q03qyFMd0

Elranatamab plus daratumumab and lenalidomide is safe and manageable, and elicited a confirmed ORR of 97.3% in patients with transplant-ineligible multiple myeloma. #mmsm #ASCO25 | ASCO hubs.li/Q03qMtz40

The European Commission has approved brentuximab vedotin in combination with ECADD chemotherapy as a treatment for adult patients with newly diagnosed stage IIb with risk factors, stage III, and stage IV Hodgkin lymphoma. #lymsm hubs.li/Q03qMt5Z0

Talquetamab elicited durable objective response rates and promising survival outcomes, with a manageable safety profile in relapsed/refractory multiple myeloma. #mmsm #ASCO25 | ASCO hubs.li/Q03qMtnB0

At a median follow-up of 16.5 months, the PFS with savolitinib plus osimertinib was 8.2 months compared with 4.5 months with chemotherapy (stratified HR, 0.34; 95% CI, 0.23-0.49; P < .0001) in EGFR-mutant, MET-amplified advanced NSCLC. #lcsm #NSCLC #ASCO25 | ASCO

Data from the phase 3 NATALEE trial confirms ribociclib plus NSAI consistently improves survival outcomes in stage II/III HR+/HER2– early breast cancer patients, regardless of age or menopausal status. #bcsm #ASCO25 hubs.ly/Q03qMxNy0

The investigator-assessed DCR was 84.0%, and was 81.5% per BICR with sevabertinib in patients with HER2-mutant NSCLC who received prior treatment excluding a HER2-targeted therapy, or who were treatment-naïve for advanced disease. #lcsm #NSCLC #ASCO25 hubs.li/Q03qMyml0

For patients with unresectable vulvar cancer, an improved ORR was observed with pembrolizumab plus cisplatin and RT, followed by maintenance pembrolizumab. #gyncsm #ASCO25 hubs.li/Q03qZn6x0

🎬 Behind the scenes at CancerNetwork’s #FaceOFF! Filmed live at #ASCO25, two expert teams stepped into the ring to debate LR-MDS—from ESA timing to trial data and treatment sequencing. Hosted by Mikkael Sekeres, MD, MS. The teaser and full video drop soon. Stay tuned!

6 or more cycles of induction chemotherapy led to significantly prolonged PFS and OS, enhancing the efficacy of first-line atezolizumab combined with chemotherapy in patients with ES-SCLC. #lcsm #SCLC #RadOnc hubs.li/Q03qZn6W0

RET rechallenge following disease progression demonstrated greater efficacy with select combination therapies targeting bypass resistance vs single agents in NSCLC. #NSCLC #lcsm #ASCO25 hubs.li/Q03qZpc50

Elraglusib plus gemcitabine/nab-paclitaxel had superior overall survival vs gemcitabine/nab-paclitaxel alone for patients with metastatic pancreatic ductal adenocarcinoma. #pancsm #ASCO25 hubs.li/Q03qZqFF0

HCPs recognize the importance of tailoring individual needs of patients living with anemia due to myelodysplastic syndromes. Read about a first-line treatment option and perspective from Ashish Shah, DO. #MDS hubs.li/Q03r6-P40

The MammaPrint assay can help with treatment decision-making by identifying older patients who may benefit from chemotherapy for high-risk early-stage breast cancer, according to Reshma L. Mahtani, DO. #bcsm | Reshma Mahtani hubs.li/Q03qZpxN0

Panelists discuss how ctDNA clearance rates during and after adjuvant chemotherapy in the BESPOKE trial provide critical insights into treatment efficacy and may serve as an early predictor of long-term patient outcomes. #crcsm | John Marshall Mark Lewis, MD, FASCO hubs.li/Q03qZq1b0

Results from the phase 1/2 OVATION-2 trial demonstrated numerical OS and PFS improvements among patients with newly diagnosed epithelial ovarian cancer who received perioperative IMNN-001 plus chemotherapy. #gyncsm #ASCO25 hubs.li/Q03qZrG50

The combination immunotherapy approach is superior to monotherapy for most patients with melanoma, with specific exceptions such as desmoplastic melanoma where monotherapy shows remarkably high response rates. #melsm hubs.li/Q03qZBwJ0

🚨Check out our top 5 posts from this week🚨 1. hubs.li/Q03qZx9s0 2. hubs.li/Q03qZyHS0 3. hubs.li/Q03qZzX70 4. hubs.li/Q03qZzW70 5. hubs.li/Q03qZyCn0 #ASCO25 #crcsm #pcsm